Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 10:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Active Ulcerative Colitis Clear all
Terminated Phase 3 Interventional Results available

The Safety and Tolerability of Budesonide Foam in Participants With Active Ulcerative Proctitis or Proctosigmoiditis

NCT01349673
View directory record Official record
Conditions
Proctitis, Proctosigmoiditis
Interventions
Budesonide Foam
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Sep 3, 2026, 10:15 AM EDT
Terminated Phase 2 Interventional Results available

VTX002 Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis

NCT05156125
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
VTX002, Placebo
Drug
Lead sponsor
Oppilan Pharma Ltd
Industry
Eligibility
18 Years to 80 Years
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
19
States / cities
Garden Grove, California • Lancaster, California • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Sep 3, 2026, 10:15 AM EDT
Terminated Phase 1 Interventional

ABI-M201 in Adult Subjects With Mildly-to-Moderately Active Ulcerative Colitis

NCT03923478
View directory record Official record
Conditions
Ulcerative Colitis Chronic Mild, Ulcerative Colitis Chronic Moderate
Interventions
ABI-M201, Placebo
Drug
Lead sponsor
Assembly Biosciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
10
States / cities
Oakland, California • San Carlos, California • Decatur, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2021 · Synced Sep 3, 2026, 10:15 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Budesonide Foam for Participants With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis

NCT01008410
View directory record Official record
Conditions
Proctitis, Proctosigmoiditis
Interventions
Budesonide, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
63
States / cities
Birmingham, Alabama • Huntsville, Alabama • Jonesboro, Arkansas + 60 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Sep 3, 2026, 10:15 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Budesonide Foam for Participants With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis

NCT01008423
View directory record Official record
Conditions
Proctitis, Proctosigmoiditis
Interventions
Budesonide, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
281 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
62
States / cities
Dothan, Alabama • Mesa, Arizona • Tucson, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Sep 3, 2026, 10:15 AM EDT
Completed Phase 3 Interventional Results available

A Study of Abatacept in Patients With Active Ulcerative Colitis

NCT00410410
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
abatacept (ABA), placebo, abatacept
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
591 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
50
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 43 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2015 · Synced Sep 3, 2026, 10:15 AM EDT
Completed Phase 3 Interventional Results available

Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis

NCT03945188
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Etrasimod, Placebo
Drug
Lead sponsor
Arena Pharmaceuticals
Industry
Eligibility
16 Years to 80 Years
Enrollment
433 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
67
States / cities
Dothan, Alabama • Sun City, Arizona • Lancaster, California + 53 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2022 · Synced Sep 3, 2026, 10:15 AM EDT
Recruiting Phase 3 Interventional

A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis

NCT07196748
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Icotrokinra, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
12 Years and older
Enrollment
882 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
55
States / cities
Chandler, Arizona • Litchfield Park, Arizona • Scottsdale, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 3, 2026, 10:15 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

NCT02407236
View directory record Official record
Conditions
Colitis, Ulcerative, Inflammatory Bowel Diseases
Interventions
Placebo IV, Placebo SC, Ustekinumab IV, Ustekinumab SC
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
961 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
68
States / cities
Birmingham, Alabama • La Mirada, California • Los Angeles, California + 65 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 3, 2026, 10:15 AM EDT
Completed Phase 1 Interventional

A Study to Assess the Safety and Pharmacokinetics of Subcutaneously Administered Golimumab, a Human Anti-TNFα Antibody, in Pediatric Patients With Moderate to Severe Active Ulcerative Colitis

NCT01900574
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Golimumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
2 Years to 17 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
9
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated May 10, 2023 · Synced Sep 3, 2026, 10:15 AM EDT
Active, not recruiting Phase 4 Interventional

Determination of the Optimal Treatment Target in Ulcerative Colitis

NCT04259138
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Treatment Algorithm A, Treatment Algorithm B, Treatment Algorithm C
Biological
Lead sponsor
Alimentiv Inc.
Other
Eligibility
18 Years and older
Enrollment
672 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
5
States / cities
Ypsilanti, Michigan • New York, New York • Asheville, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Sep 3, 2026, 10:15 AM EDT
Completed Phase 1 Interventional

Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis

NCT01759056
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
AVX 470, Placebo
Drug
Lead sponsor
Avaxia Biologics, Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
9
States / cities
Anaheim, California • Lakewood, Colorado • Winter Park, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2014 · Synced Sep 3, 2026, 10:15 AM EDT
Completed Phase 3 Interventional

A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC)

NCT04630028
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Ustekinumab Dose Based on BSA and Body Weight, Matching Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
2 Years to 17 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
9
States / cities
Wilmington, Delaware • Atlanta, Georgia • Rochester, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 3, 2026, 10:15 AM EDT
Completed Phase 2Phase 3 Interventional

Safety and Efficacy of OP2000 (Deligoparin) in the Treatment of Active Ulcerative Colitis

NCT00033943
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
deligoparin
Drug
Lead sponsor
Incara Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
33
States / cities
Anaheim, California • Orange, California • Lakewood, Colorado + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 3, 2026, 10:15 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Active Ulcerative Colitis

NCT00408629
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
adalimumab, placebo
Biological
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
518 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
36
States / cities
Anaheim, California • Wheat Ridge, Colorado • Hamden, Connecticut + 29 more
Source: ClinicalTrials.gov public record
Updated May 2, 2011 · Synced Sep 3, 2026, 10:15 AM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC)

NCT02819635
View directory record Official record
Conditions
Ulcerative Colitis (UC)
Interventions
Placebo, Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
16 Years to 75 Years
Enrollment
1,302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
149
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 114 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2022 · Synced Sep 3, 2026, 10:15 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy&Safety of ALTB-168 in Patients With Moderate to Severe Active,Anti-TNF Alpha and/or Anti-integrin Refractory UC

NCT03298022
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
ALTB-168
Biological
Lead sponsor
AltruBio Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
11
States / cities
Little Rock, Arkansas • Newport Beach, California • Hialeah, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2024 · Synced Sep 3, 2026, 10:15 AM EDT
Completed Phase 2Phase 3 Interventional Results available

BI655130 (SPESOLIMAB) Induction Treatment in Patients With Moderate-to-severe Ulcerative Colitis

NCT03482635
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Spesolimab, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
13
States / cities
Hamden, Connecticut • Miami, Florida • Orlando, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Sep 3, 2026, 10:15 AM EDT
Terminated Phase 2 Interventional Results available

A Study With GB004 in Adult Subjects With Active Ulcerative Colitis (UC)

NCT04556383
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
GB004, Placebo
Drug
Lead sponsor
GB004, Inc.
Industry
Eligibility
18 Years and older
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
13
States / cities
Encinitas, California • Lancaster, California • Baton Rouge, Louisiana + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2023 · Synced Sep 3, 2026, 10:15 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Study of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis

NCT01016262
View directory record Official record
Conditions
Proctitis, Ulcerative
Interventions
MAX-002, Placebo, Canasa®
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
22
States / cities
Birmingham, Alabama • Dothan, Alabama • Tucson, Arizona + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Sep 3, 2026, 10:15 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Efficacy & Safety of TD-1473 in Ulcerative Colitis

NCT03758443
View directory record Official record
Conditions
Ulcerative Colitis (UC)
Interventions
TD-1473 Dose A, TD-1473 Dose B, TD-1473 Dose C, Placebo
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
18 Years and older
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
38
States / cities
Chula Vista, California • La Jolla, California • Lancaster, California + 34 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Sep 3, 2026, 10:15 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Study in Patients With Moderate to Severe Active Ulcerative Colitis.

NCT03675477
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
SHR0302, Placebo
Drug
Lead sponsor
Reistone Biopharma Company Limited
Industry
Eligibility
18 Years to 75 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
3
States / cities
Lake Wales, Florida • Tampa, Florida • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jun 1, 2023 · Synced Sep 3, 2026, 10:15 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis

NCT06257875
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Lutikizumab, Adalimumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
48
States / cities
Chula Vista, California • Coronado, California • Huntington Beach, California + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Sep 3, 2026, 10:15 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

NCT05528510
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Guselkumab Dose 1, Guselkumab Dose 2, Guselkumab Dose 3, Placebo
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
32
States / cities
Litchfield Park, Arizona • Apple Valley, California • Lancaster, California + 26 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 3, 2026, 10:15 AM EDT